Skip to content

Anesthésie intraveineuse chez l’obèse : étude des posologies de propofol et de rémifentanil (étude multicentrique, prospective, ouverte comparant un groupe de patients obèses et un groupe de patients de poids normal) - Drone-Obésité

Anesthésie intraveineuse chez l’obèse : étude des posologies de propofol et de rémifentanil (étude multicentrique, prospective, ouverte comparant un groupe de patients obèses et un groupe de patients de poids normal) - Drone-Obésité

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2008-000537-22-FR
Enrollment
70
Registered
2008-05-19
Start date
2008-07-21
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

general anaesthesia MedDRA version: 9.1 Level: LLT Classification code 10002323 Term: Anesthesia general

Interventions

Trade Name: Propofol Frésénius Product Name: Propofol Pharmaceutical Form: Intravenous infusion Trade Name: Ultiva Product Name: Ultiva Pharmaceutical Form: Powder for solution for infusion

Sponsors

Hopital Foch
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients scheduled for a bariatric coelioscopic surgical procedure (obese patients) ou for a SUS-OBOLICAL coelioscopic surgical procedure (lean patients) Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - age lower than 18 years, - pregnant woman, - presence of a central neurological disorder or a lesion cerebral, of a severe respiratory or hepatic insufficiency, - allergy to propofol, or to soja or to peanuts, or to sufentanil, or to remifentanil, or to morphine, or to a muscle myorelaxant, or to an excipient, - hypersensibility to sufentanil, or to remifentanil or to another derivate of fentanyl, - allergy to latex, - presence of a gastroesophageal reflux or of a hiatal hernia, - patients receiving a psychotropic treatment or a agonist-antagonist opiate, - presence of predictive signs of difficult mask ventilation of difficult intubation (else than obesity).

Design outcomes

Primary

MeasureTime frame
Main Objective: The main objective of the study is to sompare the porpofol and remifentanil doses required to maintain the bispectral index in the range 40-0 in two groups of patients: - obese patients - lean patients.;Secondary Objective: The secondary objectives are intraoperative haemodynamic profile, time to extubation and the performances of the automated system of propfol and remifentanil delivery.;Primary end point(s): Dose of propofol administered intraoperatively

Countries

France

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026